Results 21 to 30 of about 156,165 (266)

Estimation of the Distribution of Duration of Breastfeeding from Cross-Sectional Data: Some Methodological Issue.

open access: yesJournal of Biostatistics and Epidemiology, 2021
Background: Duration of breastfeeding is an important health indicator of mother and child. There are various indirect epidemiological methods available to estimate the duration of breastfeeding from cross sectional data.
Anup Kumar   +4 more
doaj   +1 more source

Modified Weighted Kaplan-Meier Estimator

open access: yesPakistan Journal of Statistics and Operation Research, 2007
En muchos estudios médicos, la mayoría de los sujetos del estudio no llegan al evento de interés durante el período de estudio. En tales situaciones, el estimador de Kaplan Meier puede estimar las probabilidades de supervivencia para la observación censurada.
Mohammad Shafiq   +2 more
openaire   +2 more sources

Kaplan-Meier Survival Analysis: Practical Insights for Clinicians

open access: yesActa Médica Portuguesa
This article aims to provide a guide that will help healthcare professionals and clinical researchers from all fields that deal with Kaplan-Meier curves.
António Pedro Gomes   +4 more
doaj   +1 more source

Doubly robust estimator of risk in the presence of censoring dependent on time-varying covariates: application to a primary prevention trial for coronary events with pravastatin

open access: yesBMC Medical Research Methodology, 2020
Background In the presence of dependent censoring even after stratification of baseline covariates, the Kaplan–Meier estimator provides an inconsistent estimate of risk.
Takuya Kawahara   +2 more
doaj   +1 more source

Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis

open access: yesBMC Medical Research Methodology, 2016
Background The difference in restricted mean survival time ( rmstD t ∗ $$ rmstD\left({t}^{\ast}\right) $$ ), the area between two survival curves up to time horizon t ∗ $$ {t}^{\ast } $$ , is often used in cost-effectiveness analyses to estimate the ...
Béranger Lueza   +4 more
doaj   +1 more source

Time-to-event analysis

open access: yesPerspectives in Clinical Research
Survival analysis (or time-to-event analysis) deals with data where the outcome of interest is the length of time until the occurrence of an event. This type of analysis is unique because the event may not occur in all participants (known as censoring ...
Priya Ranganathan   +2 more
doaj   +1 more source

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman   +17 more
wiley   +1 more source

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients

open access: yesFrontiers in Oncology, 2022
BackgroundStudies providing more evidence to guide adjuvant chemotherapy decisions in elderly colon cancer patients are expected. MethodsWe obtained data from the Surveillance, Epidemiology and End Results (SEER) database between 2004 and 2012.
Xin Chen   +8 more
doaj   +1 more source

Robust bias estimation for Kaplan–Meier survival estimator with jackknifing [PDF]

open access: yesJournal of Statistical Theory and Practice, 2015
17 pages, 3 figures, 5 tables. CRiSM working paper, Paper No.
Khan, Md. Hasinur Rahaman   +1 more
openaire   +3 more sources

Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens.
Matthew T. McEvoy   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy